Asystolic Cardiac Arrest and Abrupt Long-Term Use Psychostimulant Suspension: A Case Report

Martin Fritzsche, Pablo Born, Pablo Toro and Matías González*

Consultation-Liaison Psychiatry Unit, Department of Psychiatry, School of Medicine, Pontifical Catholic University of Chile, Chile

Submission: May 26, 2019; Published: June 20, 2019

*Corresponding author: Matías González, Consultation-Liaison Psychiatry Unit, Department of Psychiatry, School of Medicine, Pontifical Catholic University of Chile, Chile, Santiago, Chile, Diagonal Paraguay 362, 5th floor, Santiago Centro, Santiago, Chile

Abstract

Objective: To illustrate a potential serious cardiovascular side effect occurring after abrupt long-term use psychostimulant suspension.

Introduction: Medications for attention deficit disorder with hyperactivity (ADHD): Amphetamine, Atomoxetine and Methylphenidate are widely used among general population. Prescription of psychostimulants should be cautious given reports of serious cardiovascular events in adults.

Case presentation: A 35-year-old female patient with a history of ADHD and Obsessive-compulsive disorder (OCD). Long term levothyroxine, lamotrigine, methylphenidate, modafinil and sertraline user. She presented with two-day history of abdominal pain, vomiting and progressive altered level of consciousness. Lab tests showed a pH 7.01, HCO$_3$ 5 mEq/L, serum creatinine 1.3 mg/dL blood urea nitrogen 21 mg/dL, K$^+$ 5.2 mEq/L, Anion gap 43, osmolar gap 28 and positive ketonemia.

Toxilab results: Blood acetaminophen levels < 1.2 mg/L. Urine drug panel positive for benzodiazepines, sertraline, diphenhydramine, lithium < 0.05 mmol/L, blood salicylate levels < 3.0 μmol/L, B-hCG negative. Head CT and electroencephalography showed no pathological findings. She was admitted with a diagnosis of severe metabolic acidosis possibly secondary to intoxication. During hospitalization, after adequate acid-base and hydro electrolytic correction, patient presented a self-limited episode of Torsade de pointes that evolved into asystole, from which she recovered favorably.

Discussion: Abrupt methylphenidate suspension can be potentially deleterious. Future research about cardiovascular security in adults and long-term users is suggested.

Keywords: Psychostimulant; Methylphenidate; Cardiac Arrest; Cardiovascular Safety; Adverse Effects

Abbreviations: ADHD: Attention Deficit and Hyperactivity Disorder; OCD: Obsessive Compulsive Disorder; CV: Cardiovascular; TdP: Torsade de Pointes; CAM: Confusion Assessment Method; ICU: Intensive Care Unit; ICD: Implantable Cardioverter Defibrillator

Introduction

Among the drugs used for ADHD [1], amphetamine derivatives, atomoxetine and methylphenidate are broadly used by general population. US reports show that 2.7 million children and adolescents and 1.5 million adults are currently methylphenidate users [2]. Population studies regarding CV safety in children and adolescents show this would be a reasonably safe drug [3]. On the other hand, since 1986 it has been suggested an association, although not frequent, with adverse CV effects [4]. There are reports that suggest that its use should be cautious in adults given that, although adverse effects be rare, they might be potentially fatal [3,5].

B-agonists' adrenergic effect in heart rate and blood pressure have been thoroughly described [6]. Recent reports have shown association between methylphenidate and syncope, arrhythmias and sudden death, mainly on the first days of treatment and among patients with congenital heart disease [3,7,8]. This association is stronger at lower doses of methylphenidate, therefore suggesting a non-causal association [9]. There are several reports of cardiovascular side effects of methylphenidate in children and adolescents. In adults, however, it remains yet unclear mainly due to lack of research. Nonetheless, there is a study showing similar results to those in children [9], as well as possible side effects at withdrawal. One study carried out in children and adolescents
in which the drug washout period was followed up found an increased rate of arrhythmias after seven days of discontinuation of methylphenidate [3]. This article’s purpose is to illustrate, by a clinical case, a potential serious cardiovascular side effect of abrupt long-term use psychostimulant suspension.

Case Presentation

A 35-year-old female patient, single, kinesiologist. She lived with her parents and didn’t have children. She first attended mental health services at age 15, when she was diagnosed with OCD [1] and ADHD [1]. During college she presented with a mood disorder for which she started proper treatment. Two years ago, after a work conflict and subsequent worsening of her OCD, she restarted follow-up. She also had a medical record of hypothyroidism. She was regularly using levotyroxine, lamotrigine, methylphenidate, modafinil and sertraline (Table 1).

Table 1: Previous regular use medications and dose.

| Medication         | Dose         |
|--------------------|--------------|
| Levotyroxine       | 200 mcg qd   |
| Aripiprazole       | 5 mg qd      |
| Lamotrigine        | 125 mg qd    |
| Methylphenidate Retard | 40 mg qd |
| Modafinil          | 200 mg qd    |
| Sertraline         | 225 mg qd    |

Patient was brought to the emergency service with a two-day history of abdominal pain and vomiting, which evolved to progressive alteration of mental status. Patients and relatives denied any recent change in medication doses or any substance abuse. At presentation patient was agitated, hemodynamically stable, slightly tachycardic, afebrile. Lab tests showed a pH 7.01, HC0₂₃ 21 mEq/L, serum creatinine 1.3 mg/dL, blood urea nitrogen 21 mg/dL, K⁺ 5.2 mEq/L, anion gap 43, osmolar gap 28 and positive ketonemia. Toxilab drug screening results: blood acetaminophen levels < 1.2 mg/L, Urine drug panel positive for benzodiazepines, sertraline, diphenhydramine, lithium < 0.05 mmol/L, blood salicylate levels < 3.0 μg/mL, β-hCG negative. Head CT and electroencephalography didn’t show pathological findings nor epilepticiform activity.

Patient was admitted to a monitored unit with the diagnoses of severe metabolic acidosis of undetermined cause and acute kidney injury. Early fluid replacement was started along with bicarbonate solution, thiamine, folic acid and B6 vitamin administration. Lorazepam was given for agitation control. Adequate acid-base and hydro electrolytic balance was achieved, along with proper kidney function recovery, without need for renal replacement therapy. Chronic use drugs were held suspended.

She was evaluated by the hospital’s consultation-liaison psychiatry unit due to suspected intoxication. At first, a formal interview was impossible due to consciousness impairment (she tested positive on CAM evaluation) [10]. None of the previously used psychotropic medication was reintroduced. Lorazepam was prescribed in cases of anxiety, insomnia or psychomotor agitation. Reevaluated twenty-four hours later patient was vigilant and orientated in time and space. She denied any recent alcohol, tobacco or other substance use. She denied self-injurious behavior or any suicide attempts. During interview she impressed exhausted. On mental examination patient was described drowsy, uncooperative, querulous and childish. She had a fluid and coherent speech, although poorly spontaneous and bradypsychic. Mood was euthymic, with emotional lability and crying at remembrance of romantic relationships, and spontaneous smiling. She had poor insight. Didn’t show psychotic symptoms.

Afterwards, she evolved with persistent symptomatic sinus bradycardia down to 37 bpm. A rhythm Holter monitoring was performed. On the fifth day of stay she presented an episode of Torsade de Pointes which manifested as syncope, evolving into ventricular fibrillation and a subsequent 47-second-long asystole. The entire episode lasted three minutes. Earlier that day blood lab tests showed pH 7.4, HC0₂₃ 21 mEq/L, K⁺ 3.6 mEq/L, mEq/L Mg 1.6 mg/dL. Magnesium sulphate was apported, with recovery of sinus rhythm. She was then transferred to the hospital ICU, where isoproterenol was started along with clobazam due to initial suspicion of a convulsive episode, which was discarded later by neurology consultants. Rest electrocardiography performed previous to TdP episode showed a corrected QT (QTC) of 470 ms. Following electrocardiographic study showed a QTC of 520 ms. Echocardiography didn’t reveal structural heart lesions.

Patient was started on low dose bisoprolol. She did not meet indications for neither ICD nor pacemaker. Ventricular fibrillation was attributed to toxic-metabolic derangement. She was kept on oral magnesium and potassium supplementation. Electrophysiology consultants approved restart of psychotropic medication under close electrocardiographic monitoring. Olanzapine was started for impulsivity symptoms management, medication under close electrocardiographic monitoring. Following electrocardiographic study showed a QTc of 470 ms. Olanzapine was started for impulsivity symptoms management, medication under close electrocardiographic monitoring. Following electrocardiographic study showed a QTc of 470 ms. Olanzapine was started for impulsivity symptoms management, medication under close electrocardiographic monitoring. Following electrocardiographic study showed a QTc of 470 ms. Olanzapine was started for impulsivity symptoms management, medication under close electrocardiographic monitoring. Following electrocardiographic study showed a QTc of 470 ms.

Among other studies performed during her stay, a lumbar puncture was performed, with a cerebrospinal fluid study that showed hyperproteinorachia, slightly elevated IgG index, negative for oligoclonal bands, negative autoimmune encephalitis panel and negative Gram stain and culture. Given following favourable clinical evolution, with stabilization of behavioral symptoms and satisfactory acid-base and electrolyte balance, patient was discharged with an ambulatory follow-up plan.

Discharge diagnosis

i. Solved, Anion gap metabolic acidosis (SC73.2) [11]
ii. Solved, Polymorphic ventricular tachycardia (TP), Ventricular fibrillation, Asystolic cardiac arrest (BC71.01, BC71.1, MC82.2) [11]
iii. Attention deficit hyperactivity disorder (314.01) [1]
iv. Hypothyroidism (5A00) [11]

Discussion

The presented case shows a patient with prolonged psychostimulants use, methylphenidate and modafinil, both having a synergic effect. Five days after abrupt suspension, patient presents an ominous event: TdP and a 47 second asystole. Former potentially QT prolonging medication had been suspended, with minimal attributable role to current event. And although a major acid-base disorder existed at presentation, at the time of the arrhythmia it had already been corrected. Given there was no evident cause to this event, we might consider - as has been proposed in literature [3] - the effect of psychostimulant suspension as a possible trigger.

It seems reasonable to suggest more extensive research regarding psychostimulant cardiovascular safety adults. Besides, it's medical indication should be regarded cautious and always supervised. Informal and irregular use is otherwise frequent with these medications, which is not free from hazard and might bring even fatal consequences. Lastly, it is important to keep in mind the effects of medication suspension - commonly at admission - when facing intercurrences like the one described in this case.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

1. Diagnostic and statistical manual of mental disorders (2013) (5th ed.), American Psychiatric Association, USA.
2. Nissen SE (2006) ADHD drugs and cardiovascular risk. N Engl J Med 354: 1445-1448.
3. Shin JY, Roughhead EE, Park BJ, Pratt NL (2016) Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self-controlled case series study. BMJ 2550.
4. Lucas PB, Gardner DL, Wolowitz OM, Tucker EE, Cowdry RW (1986) Methylphenidate-Induced Cardiac Arrhythmias. N Engl J Med 315(23): 1405-1405.
5. Montastruc F, Montastruc G, Montastruc JL, Revet A (2016) Cardiovascular safety of methylphenidate should also be considered in adults. BMJ i3418.
6. Hammerness PG, Wikens T, Berul C, Elkort M (2008) Supraventricular tachycardia in an adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 42: 219-220.
7. Zhang C, Kutyifa V, Moss AJ, McNitt S, Zareba W, et al. (2015) Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. J Cardiovasc Electrophysiol 26(10): 1039-1044.
8. Kaltman JR, Berul CI (2015) Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business. J Cardiovasc Electrophysiol 26(10): 1045-1047.
9. Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, et al. (2012) Methylphenidate and Risk of Serious Cardiovascular Events in Adults. Am J Psychiatry 169(2): 178-185.
10. González M, de Pablo J, Fuente E, Valdés M, Peri JM, et al. (2004) Instrument for Detection of Delirium in General Hospitals: Adaptation of the Confusion Assessment Method. Psychosomatics 45(5): 426-431.
11. World Health Organization (2018) International statistical classification of diseases and related health problems (11th Revision).